<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AFATINIB" rxcui="1430438">
<ATC code="L01XE13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>It is recommendedthat the erythromycin be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALFENTANIL" rxcui="480">
<ATC code="N01AH02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the opioid analgesic&#39;s effect of respiratory depression due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Adjust the dosage of the alfentanil when administered with the erythromycin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUSPIRONE" rxcui="1827">
<ATC code="N05BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEXAMETHASONE" rxcui="3264">
<ATC code="A01AC02" />
<ATC code="C05AA09" />
<ATC code="D07AB19" />
<ATC code="D07XB05" />
<ATC code="D10AA03" />
<ATC code="H02AB02" />
<ATC code="R01AD03" />
<ATC code="S01BA01" />
<ATC code="S01CB01" />
<ATC code="S02BA06" />
<ATC code="S03BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing&#39;s syndrome</DESCRIPTION>
<SEVERITY>Take into account </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to increase of its absorption </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="EBASTINE" rxcui="23796">
<ATC code="R06AX22" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FIDAXOMICIN" rxcui="1111103">
<ATC code="A07AA12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fidaxomicin</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIBENCLAMIDE" rxcui="4815">
<ATC code="A10BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GLIMEPIRIDE" rxcui="25789">
<ATC code="A10BD06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LUMEFANTRINE" rxcui="847728">
<ATC code="P01BF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIZOLASTINE" rxcui="61455">
<ATC code="R06AX25" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PRAVASTATIN" rxcui="42463">
<ATC code="C10AA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring during the treatment with the antibiotic.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VENLAFAXINE" rxcui="39786">
<ATC code="N06AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the concentrations of venlafaxine with risk of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>210-ERYTHROMYCIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VINCA ALKALOIDS" code="L01CA" /></DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical and biological monitoring. Possibly use another antibiotic.</COMMENT>
</INTERACTION>
</INTERACTIONS>
